Biodel appoints new CMO

Dr Andreas Pfuetzner, Biodel’s current chief medical officer (CMO) will remain on Biodel’s management team as the company’s CMO in Europe and as a member of the company’s scientific advisory board.

Dr Krasner joins the company from Pfizer Global Research and Development where he was director of the Department of Clinical Research Metabolic Diseases and responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates.

Solomon Steiner, CEO and chairman of Biodel, said: “Dr Krasner’s depth of knowledge in endocrinology and insulin, coupled with his experience developing late stage drug candidates will be valuable in advancing our suite of VIAject products to market.”